Finding new small molecules to target TREM2 for Alzheimer's treatment
Discovery of first-in-class small molecule TREM2 ligands as therapeutics for Alzheimer's disease
This study is looking for new small drugs that can help a specific receptor in the brain called TREM2, which is important for reducing inflammation and clearing harmful plaques in Alzheimer's disease, with the hope of finding better treatments for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11097248 on NIH RePORTER |
What this research studies
This research focuses on developing small molecule ligands that can target the TREM2 receptor, which plays a crucial role in regulating inflammation in Alzheimer's disease. By utilizing a novel platform called Small Molecules from Antibody Pharmacophores (SMAPs), the researchers aim to identify compounds that can enhance the receptor's ability to clear amyloid plaques and reduce neuroinflammation. The approach involves creating pharmacophore maps based on the structures of antibodies bound to immune cell receptors, allowing for the discovery of small molecules that can effectively modulate TREM2 function. This innovative strategy seeks to overcome the limitations of current antibody-based therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who are experiencing symptoms related to neuroinflammation.
Not a fit: Patients with other forms of dementia or those who do not have Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that effectively reduce inflammation and improve outcomes for patients with Alzheimer's disease.
How similar studies have performed: While targeting TREM2 with antibodies has been explored, this approach of using small molecules is novel and has not been extensively tested in clinical settings.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Gabr, Moustafa — Weill Medical Coll of Cornell Univ
- Study coordinator: Gabr, Moustafa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.